JP2018533912A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018533912A5 JP2018533912A5 JP2018513360A JP2018513360A JP2018533912A5 JP 2018533912 A5 JP2018533912 A5 JP 2018533912A5 JP 2018513360 A JP2018513360 A JP 2018513360A JP 2018513360 A JP2018513360 A JP 2018513360A JP 2018533912 A5 JP2018533912 A5 JP 2018533912A5
- Authority
- JP
- Japan
- Prior art keywords
- alanine
- amino acid
- ckp
- phenylalanine
- acid selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960003767 alanine Drugs 0.000 claims 219
- 150000001413 amino acids Chemical class 0.000 claims 195
- 229940024606 amino acid Drugs 0.000 claims 158
- 235000001014 amino acid Nutrition 0.000 claims 158
- -1 3-quinolinyl Chemical group 0.000 claims 76
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 claims 49
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 47
- 229960002429 proline Drugs 0.000 claims 43
- 239000004471 Glycine Substances 0.000 claims 38
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 30
- XWHHYOYVRVGJJY-QMMMGPOBSA-N 4-fluoro-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(F)C=C1 XWHHYOYVRVGJJY-QMMMGPOBSA-N 0.000 claims 26
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 26
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 22
- 229910052731 fluorine Inorganic materials 0.000 claims 19
- 229910052757 nitrogen Inorganic materials 0.000 claims 17
- 229910052727 yttrium Inorganic materials 0.000 claims 16
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 14
- 229910052700 potassium Inorganic materials 0.000 claims 14
- YCFIGDBZIONWCE-ZETCQYMHSA-N (2S)-2-[(4-methylpyridin-2-yl)amino]propanoic acid Chemical compound CC1=CC(=NC=C1)N[C@@H](C)C(=O)O YCFIGDBZIONWCE-ZETCQYMHSA-N 0.000 claims 13
- QGFVUADZXXJSDI-QMMMGPOBSA-N (2s)-2-amino-3-(2-chloro-4-hydroxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1Cl QGFVUADZXXJSDI-QMMMGPOBSA-N 0.000 claims 13
- BOLUZPBFHZSEQD-JTQLQIEISA-N (2s)-2-amino-3-(2-ethyl-4-hydroxyphenyl)propanoic acid Chemical compound CCC1=CC(O)=CC=C1C[C@H](N)C(O)=O BOLUZPBFHZSEQD-JTQLQIEISA-N 0.000 claims 13
- NRCSJHVDTAAISV-QMMMGPOBSA-N (2s)-2-amino-3-(3,4-dichlorophenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(Cl)C(Cl)=C1 NRCSJHVDTAAISV-QMMMGPOBSA-N 0.000 claims 13
- AXEOMQHKTSGLGS-VIFPVBQESA-N (2s)-2-amino-3-(4-hydroxy-2-methylphenyl)propanoic acid Chemical compound CC1=CC(O)=CC=C1C[C@H](N)C(O)=O AXEOMQHKTSGLGS-VIFPVBQESA-N 0.000 claims 13
- DQLHSFUMICQIMB-VIFPVBQESA-N (2s)-2-amino-3-(4-methylphenyl)propanoic acid Chemical compound CC1=CC=C(C[C@H](N)C(O)=O)C=C1 DQLHSFUMICQIMB-VIFPVBQESA-N 0.000 claims 13
- XFGVJLGVINCWDP-BKLSDQPFSA-N (2s)-2-amino-5,5,5-trifluoro-4-methylpentanoic acid Chemical compound FC(F)(F)C(C)C[C@H](N)C(O)=O XFGVJLGVINCWDP-BKLSDQPFSA-N 0.000 claims 13
- FZENWFNLDOYYFB-YFKPBYRVSA-N (2s)-2-azaniumyl-2-cyclobutylacetate Chemical compound [O-]C(=O)[C@@H]([NH3+])C1CCC1 FZENWFNLDOYYFB-YFKPBYRVSA-N 0.000 claims 13
- XBPKRVHTESHFAA-LURJTMIESA-N (2s)-2-azaniumyl-2-cyclopentylacetate Chemical compound OC(=O)[C@@H](N)C1CCCC1 XBPKRVHTESHFAA-LURJTMIESA-N 0.000 claims 13
- ZIWHMENIDGOELV-BKLSDQPFSA-N (2s)-4-fluoropyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CC(F)CN1 ZIWHMENIDGOELV-BKLSDQPFSA-N 0.000 claims 13
- BUZICZZQJDLXJN-GSVOUGTGSA-N (3R)-3-amino-4-hydroxybutanoic acid Chemical compound OC[C@H](N)CC(O)=O BUZICZZQJDLXJN-GSVOUGTGSA-N 0.000 claims 13
- QRRKZFCXXBFHSV-UHFFFAOYSA-N 1-ethylindole Chemical compound C1=CC=C2N(CC)C=CC2=C1 QRRKZFCXXBFHSV-UHFFFAOYSA-N 0.000 claims 13
- KJCVRFUGPWSIIH-UHFFFAOYSA-N 1-naphthol Chemical compound C1=CC=C2C(O)=CC=CC2=C1 KJCVRFUGPWSIIH-UHFFFAOYSA-N 0.000 claims 13
- JDFIJVJKRTZYCK-UHFFFAOYSA-N 1-propan-2-ylindole Chemical compound C1=CC=C2N(C(C)C)C=CC2=C1 JDFIJVJKRTZYCK-UHFFFAOYSA-N 0.000 claims 13
- SRSKXJVMVSSSHB-UHFFFAOYSA-N 1h-pyrrolo[3,2-c]pyridine Chemical compound N1=CC=C2NC=CC2=C1 SRSKXJVMVSSSHB-UHFFFAOYSA-N 0.000 claims 13
- VIIAUOZUUGXERI-ZETCQYMHSA-N 3-fluoro-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(F)=C1 VIIAUOZUUGXERI-ZETCQYMHSA-N 0.000 claims 13
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 claims 13
- 229930195711 D-Serine Natural products 0.000 claims 13
- 229940000635 beta-alanine Drugs 0.000 claims 13
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims 13
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 claims 13
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 13
- JPZXHKDZASGCLU-LBPRGKRZSA-N β-(2-naphthyl)-alanine Chemical compound C1=CC=CC2=CC(C[C@H](N)C(O)=O)=CC=C21 JPZXHKDZASGCLU-LBPRGKRZSA-N 0.000 claims 13
- PRAWYXDDKCVZTL-QMMMGPOBSA-N (2s)-2-amino-3-(3,4-difluorophenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(F)C(F)=C1 PRAWYXDDKCVZTL-QMMMGPOBSA-N 0.000 claims 12
- BLRHMMGNCXNXJL-UHFFFAOYSA-N 1-methylindole Chemical compound C1=CC=C2N(C)C=CC2=C1 BLRHMMGNCXNXJL-UHFFFAOYSA-N 0.000 claims 12
- NIGWMJHCCYYCSF-QMMMGPOBSA-N 4-chloro-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(Cl)C=C1 NIGWMJHCCYYCSF-QMMMGPOBSA-N 0.000 claims 12
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 claims 12
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 12
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 claims 12
- BEBCJVAWIBVWNZ-UHFFFAOYSA-N glycinamide Chemical compound NCC(N)=O BEBCJVAWIBVWNZ-UHFFFAOYSA-N 0.000 claims 12
- OFYAYGJCPXRNBL-LBPRGKRZSA-N naphthalen-2-yl-3-alanine Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CC=CC2=C1 OFYAYGJCPXRNBL-LBPRGKRZSA-N 0.000 claims 12
- CIVRKJUVGIVLTC-QMMMGPOBSA-N (2s)-2-amino-3-(2-chloro-1h-indol-3-yl)propanoic acid Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=C(Cl)NC2=C1 CIVRKJUVGIVLTC-QMMMGPOBSA-N 0.000 claims 11
- LPBSHGLDBQBSPI-YFKPBYRVSA-N (2s)-2-amino-4,4-dimethylpentanoic acid Chemical compound CC(C)(C)C[C@H](N)C(O)=O LPBSHGLDBQBSPI-YFKPBYRVSA-N 0.000 claims 11
- LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 claims 11
- SRGOJUDAJKUDAZ-LURJTMIESA-N (2s)-2-amino-3-cyclobutylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1CCC1 SRGOJUDAJKUDAZ-LURJTMIESA-N 0.000 claims 10
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 10
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims 10
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 10
- 229960003104 ornithine Drugs 0.000 claims 10
- 235000004279 alanine Nutrition 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- CGHUICSOQGITJK-UHFFFAOYSA-N 2-aminoacetic acid morpholine Chemical compound NCC(O)=O.C1COCCN1 CGHUICSOQGITJK-UHFFFAOYSA-N 0.000 claims 8
- 208000004644 retinal vein occlusion Diseases 0.000 claims 8
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 7
- 229910052698 phosphorus Inorganic materials 0.000 claims 7
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 claims 6
- 229960003067 cystine Drugs 0.000 claims 6
- 239000007943 implant Substances 0.000 claims 5
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims 4
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims 4
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 4
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims 4
- 206010064930 age-related macular degeneration Diseases 0.000 claims 4
- 150000001412 amines Chemical group 0.000 claims 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 4
- 201000005667 central retinal vein occlusion Diseases 0.000 claims 4
- 208000002780 macular degeneration Diseases 0.000 claims 4
- 210000004899 c-terminal region Anatomy 0.000 claims 3
- LEVWYRKDKASIDU-IMJSIDKUSA-N cystine group Chemical group C([C@@H](C(=O)O)N)SSC[C@@H](C(=O)O)N LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 238000002513 implantation Methods 0.000 claims 3
- ZKWFSTHEYLJLEL-UHFFFAOYSA-N morpholine-4-carboxamide Chemical compound NC(=O)N1CCOCC1 ZKWFSTHEYLJLEL-UHFFFAOYSA-N 0.000 claims 3
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 3
- YAKHNYUMNAQBJC-UHFFFAOYSA-N 2-aminoacetic acid;morpholine-4-carboxamide Chemical compound NCC(O)=O.NC(=O)N1CCOCC1 YAKHNYUMNAQBJC-UHFFFAOYSA-N 0.000 claims 2
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 2
- 240000006337 Ecballium elaterium Species 0.000 claims 2
- 201000002563 Histoplasmosis Diseases 0.000 claims 2
- 208000022873 Ocular disease Diseases 0.000 claims 2
- 206010073286 Pathologic myopia Diseases 0.000 claims 2
- 208000007135 Retinal Neovascularization Diseases 0.000 claims 2
- 206010038934 Retinopathy proliferative Diseases 0.000 claims 2
- 101710162629 Trypsin inhibitor Proteins 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 208000001309 degenerative myopia Diseases 0.000 claims 2
- 230000004340 degenerative myopia Effects 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 201000011190 diabetic macular edema Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 208000030533 eye disease Diseases 0.000 claims 2
- 150000002314 glycerols Chemical class 0.000 claims 2
- 150000002333 glycines Chemical class 0.000 claims 2
- 208000028867 ischemia Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 238000013268 sustained release Methods 0.000 claims 2
- 239000012730 sustained-release form Substances 0.000 claims 2
- 230000008728 vascular permeability Effects 0.000 claims 2
- 208000006542 von Hippel-Lindau disease Diseases 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 claims 1
- 206010055665 Corneal neovascularisation Diseases 0.000 claims 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims 1
- 101000609473 Ecballium elaterium Trypsin inhibitor 2 Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 101001039199 Homo sapiens Low-density lipoprotein receptor-related protein 6 Proteins 0.000 claims 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 claims 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims 1
- 229930182821 L-proline Natural products 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- 102000001774 Low Density Lipoprotein Receptor-Related Protein-6 Human genes 0.000 claims 1
- 108010015179 Low Density Lipoprotein Receptor-Related Protein-6 Proteins 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 101000808007 Mus musculus Vascular endothelial growth factor A Proteins 0.000 claims 1
- ORUQGUXXZPCBQP-UHFFFAOYSA-N NCC(=O)O.O1CCC1 Chemical class NCC(=O)O.O1CCC1 ORUQGUXXZPCBQP-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 claims 1
- 101000808006 Rattus norvegicus Vascular endothelial growth factor A Proteins 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 108010077895 Sarcosine Proteins 0.000 claims 1
- 101710204410 Scaffold protein Proteins 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 201000000159 corneal neovascularization Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- LMKPHJYTFHAGHK-UHFFFAOYSA-N cyclodrine Chemical compound C1CCCC1(O)C(C(=O)OCCN(CC)CC)C1=CC=CC=C1 LMKPHJYTFHAGHK-UHFFFAOYSA-N 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000007850 fluorescent dye Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 150000002332 glycine derivatives Chemical class 0.000 claims 1
- 102000055436 human LRP6 Human genes 0.000 claims 1
- 102000058223 human VEGFA Human genes 0.000 claims 1
- 229960003136 leucine Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000009826 neoplastic cell growth Effects 0.000 claims 1
- 125000006299 oxetan-3-yl group Chemical group [H]C1([H])OC([H])([H])C1([H])* 0.000 claims 1
- 210000001525 retina Anatomy 0.000 claims 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022096301A JP7602514B2 (ja) | 2015-09-15 | 2022-06-15 | シスチンノットスキャフォールドプラットフォーム |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562219063P | 2015-09-15 | 2015-09-15 | |
| US62/219,063 | 2015-09-15 | ||
| PCT/US2016/052012 WO2017049009A1 (en) | 2015-09-15 | 2016-09-15 | Cystine knot scaffold platform |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022096301A Division JP7602514B2 (ja) | 2015-09-15 | 2022-06-15 | シスチンノットスキャフォールドプラットフォーム |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018533912A JP2018533912A (ja) | 2018-11-22 |
| JP2018533912A5 true JP2018533912A5 (OSRAM) | 2019-10-31 |
| JP7166916B2 JP7166916B2 (ja) | 2022-11-08 |
Family
ID=57068206
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018513360A Active JP7166916B2 (ja) | 2015-09-15 | 2016-09-15 | シスチンノットスキャフォールドプラットフォーム |
| JP2022096301A Active JP7602514B2 (ja) | 2015-09-15 | 2022-06-15 | シスチンノットスキャフォールドプラットフォーム |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022096301A Active JP7602514B2 (ja) | 2015-09-15 | 2022-06-15 | シスチンノットスキャフォールドプラットフォーム |
Country Status (22)
| Country | Link |
|---|---|
| US (8) | US10428125B2 (OSRAM) |
| EP (1) | EP3350215B1 (OSRAM) |
| JP (2) | JP7166916B2 (OSRAM) |
| KR (1) | KR102846388B1 (OSRAM) |
| CN (4) | CN114591422B (OSRAM) |
| AR (1) | AR106032A1 (OSRAM) |
| AU (2) | AU2016323445B2 (OSRAM) |
| BR (1) | BR112018002263A2 (OSRAM) |
| CA (1) | CA2996006A1 (OSRAM) |
| CL (2) | CL2018000668A1 (OSRAM) |
| CO (1) | CO2018002510A2 (OSRAM) |
| CR (1) | CR20180169A (OSRAM) |
| IL (2) | IL257399B (OSRAM) |
| MA (1) | MA42828A (OSRAM) |
| MX (1) | MX2018002922A (OSRAM) |
| MY (1) | MY190552A (OSRAM) |
| PE (1) | PE20181293A1 (OSRAM) |
| PH (1) | PH12018500577A1 (OSRAM) |
| RU (1) | RU2770384C2 (OSRAM) |
| TW (1) | TWI799366B (OSRAM) |
| UA (1) | UA125505C2 (OSRAM) |
| WO (1) | WO2017049009A1 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI799366B (zh) | 2015-09-15 | 2023-04-21 | 美商建南德克公司 | 胱胺酸結骨架平臺 |
| WO2019233605A1 (en) * | 2018-06-08 | 2019-12-12 | BioNTech SE | Compositions and methods for diagnosis and treatment of cancer |
| CA3183808A1 (en) | 2020-06-11 | 2021-12-16 | Genentech, Inc. | Nanolipoprotein-polypeptide conjugates and compositions, systems, and methods using same |
| WO2025193946A2 (en) * | 2024-03-14 | 2025-09-18 | Genentech, Inc. | Peptides binding lrrc15 and uses thereof |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US918814A (en) | 1907-10-30 | 1909-04-20 | Handy Mfg Company | Funnel. |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4666884A (en) | 1984-04-10 | 1987-05-19 | New England Deaconess Hospital | Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| ATE158615T1 (de) | 1990-03-20 | 1997-10-15 | Univ Columbia | Chimäre antikörper mit rezeptor-bindenden liganden anstelle ihrer konstanten region |
| DE69303494T2 (de) | 1992-11-13 | 1997-01-16 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| US5834252A (en) | 1995-04-18 | 1998-11-10 | Glaxo Group Limited | End-complementary polymerase reaction |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| US5747035A (en) | 1995-04-14 | 1998-05-05 | Genentech, Inc. | Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor |
| WO1997043316A1 (en) | 1996-05-10 | 1997-11-20 | Beth Israel Deaconess Medical Center, Inc. | Physiologically active molecules with extended half-lives and methods of using same |
| US5961955A (en) * | 1997-06-03 | 1999-10-05 | Coulter Pharmaceutical, Inc. | Radioprotectant for peptides labeled with radioisotope |
| CZ20003099A3 (cs) | 1998-02-25 | 2002-04-17 | Lexigen Pharmaceuticals Corporation | Zvýąení doby poloviční ľivotnosti cirkulujících fúzních proteinů odvozených od protilátek |
| US20020142374A1 (en) | 1998-08-17 | 2002-10-03 | Michael Gallo | Generation of modified molecules with increased serum half-lives |
| JP2003528632A (ja) | 2000-03-31 | 2003-09-30 | インスティティ・パスツール | 血管内皮成長因子（ｖｅｇｆ）−媒介性脈管形成を阻害するペプチド、該ペプチドをエンコードするポリヌクレオチド及びその使用方法 |
| AU2001265198A1 (en) | 2000-06-01 | 2001-12-11 | Amgen Inc. | Cystine-knot polypeptides: cloaked-2 molecules and uses thereof |
| DK1355919T3 (da) | 2000-12-12 | 2011-03-14 | Medimmune Llc | Molekyler med længere halveringstider, sammensætninger og anvendelser deraf |
| DE60239868D1 (de) | 2001-06-12 | 2011-06-09 | Univ Johns Hopkins Med | Reservoirvorrichtung für die intraokulare arzneimittelabgabe |
| WO2003029275A2 (en) | 2001-10-03 | 2003-04-10 | Regeneron Pharmaceuticals, Inc. | Anti-angiogenic peptides |
| GB0130738D0 (en) | 2001-12-21 | 2002-02-06 | Serono Internat S A | Protein |
| US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
| WO2005110374A1 (en) | 2004-04-30 | 2005-11-24 | Allergan, Inc. | Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component |
| US20060182783A1 (en) | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Sustained release intraocular drug delivery systems |
| DE102005002978B4 (de) | 2005-01-21 | 2013-04-25 | Merz Pharma Gmbh & Co. Kgaa | Rekombinante Expression von Proteinen in einer disulfidverbrückten, zweikettigen Form |
| EP1844337B1 (en) | 2005-01-24 | 2013-07-03 | Pepscan Systems B.V. | Binding compounds, immunogenic compounds and peptidomimetics |
| US20060204548A1 (en) | 2005-03-01 | 2006-09-14 | Allergan, Inc. | Microimplants for ocular administration |
| JP2008546821A (ja) | 2005-06-29 | 2008-12-25 | ロゼリ、 パトリツィア | Ｖｅｇｆ受容体を制御する化合物、およびその使用 |
| CN101583370A (zh) * | 2005-09-27 | 2009-11-18 | 阿穆尼克斯公司 | 蛋白质药物及其用途 |
| WO2007038619A2 (en) * | 2005-09-27 | 2007-04-05 | Amunix, Inc. | Proteinaceous pharmaceuticals and uses thereof |
| TW200732347A (en) * | 2005-10-06 | 2007-09-01 | Trophogen Inc | VEGF analogs and methods of use |
| US7918814B2 (en) | 2006-05-02 | 2011-04-05 | Georgia Tech Research Corporation | Method for drug delivery to ocular tissue using microneedle |
| WO2008045252A2 (en) * | 2006-10-04 | 2008-04-17 | The Board Of Trustees Of The Leland Stanford Junior University | Engineered integrin binding peptides |
| US8039010B2 (en) | 2006-11-03 | 2011-10-18 | Allergan, Inc. | Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier |
| CA2670990A1 (en) | 2006-12-01 | 2008-06-12 | Allergan, Inc. | Method for determining optimum intraocular locations for drug delivery systems |
| EP2187968A4 (en) | 2007-08-21 | 2013-02-20 | Univ Texas | THERMOKINETIC MIXING FOR PHARMACEUTICAL APPLICATIONS |
| WO2009120922A2 (en) * | 2008-03-27 | 2009-10-01 | Zymogenetics, Inc. | Compositions and methods for inhibiting pdgfrbeta and vegf-a |
| US8557273B2 (en) | 2008-04-18 | 2013-10-15 | Medtronic, Inc. | Medical devices and methods including polymers having biologically active agents therein |
| US8821870B2 (en) | 2008-07-18 | 2014-09-02 | Allergan, Inc. | Method for treating atrophic age related macular degeneration |
| EP2349327A4 (en) * | 2008-10-23 | 2012-11-28 | Massachusetts Inst Technology | COMMITMENT DIRECTED FC RECEIVERS ACTIVATORS |
| WO2010060748A1 (en) * | 2008-11-03 | 2010-06-03 | Molecular Partners Ag | Binding proteins inhibiting the vegf-a receptor interaction |
| AU2010208046B2 (en) | 2009-01-29 | 2014-10-02 | Forsight Vision4, Inc. | Posterior segment drug delivery |
| US8778888B2 (en) * | 2009-11-06 | 2014-07-15 | The Board Of Trustees Of The Leland Stanford Junior University | Cystine knot peptides binding to alpha IIb beta 3 integrins and methods of use |
| US20110207653A1 (en) | 2009-12-21 | 2011-08-25 | Adrian Raiche | Microparticle Encapsulated Thiol-Containing Polypeptides Together with a Redox Reagent |
| EP2515864A4 (en) | 2009-12-23 | 2013-09-11 | Psivida Inc | DELAYED RELEASE DELIVERY DEVICES |
| US8339139B2 (en) * | 2010-01-29 | 2012-12-25 | Infineon Technologies Ag | System and method for testing a circuit |
| AU2011326164B2 (en) | 2010-11-08 | 2016-05-05 | The Board Of Trustees Of The Leland Stanford Junior University | Fusion proteins comprising an engineered knottin peptide and uses thereof |
| KR102014203B1 (ko) * | 2011-02-18 | 2019-08-26 | 아사나 바이오사이언시스 엘엘씨 | 아미노인단 화합물 및 통증 치료에서 그것의 용도 |
| US9187553B2 (en) * | 2012-01-25 | 2015-11-17 | Swey-Shen Chen | Displaying native human IgE neutralizing FcepsilonRIa-contacting IgE B-cell epitopes by constraining super beta(b)-strands and cystine knots on thermostable protein scaffold |
| JP2015528454A (ja) * | 2012-08-28 | 2015-09-28 | ノバルティス アーゲー | 眼血管増殖性疾患の処置におけるｖｅｇｆアンタゴニストの使用 |
| GB201218278D0 (en) * | 2012-10-11 | 2012-11-28 | Cyclogenix Ltd | Translocating peptide |
| WO2014063012A1 (en) * | 2012-10-19 | 2014-04-24 | The Board Of Trustees Of The Leland Stanford Junior University | Conjugated knottin mini-proteins containing non-natural amino acids |
| TWI799366B (zh) | 2015-09-15 | 2023-04-21 | 美商建南德克公司 | 胱胺酸結骨架平臺 |
-
2016
- 2016-09-14 TW TW105130077A patent/TWI799366B/zh active
- 2016-09-15 IL IL257399A patent/IL257399B/en unknown
- 2016-09-15 US US15/267,087 patent/US10428125B2/en active Active
- 2016-09-15 MX MX2018002922A patent/MX2018002922A/es unknown
- 2016-09-15 MA MA042828A patent/MA42828A/fr unknown
- 2016-09-15 AU AU2016323445A patent/AU2016323445B2/en active Active
- 2016-09-15 CR CR20180169A patent/CR20180169A/es unknown
- 2016-09-15 AR ARP160102810A patent/AR106032A1/es unknown
- 2016-09-15 CN CN202210278625.9A patent/CN114591422B/zh active Active
- 2016-09-15 MY MYPI2018000374A patent/MY190552A/en unknown
- 2016-09-15 KR KR1020187010195A patent/KR102846388B1/ko active Active
- 2016-09-15 IL IL294568A patent/IL294568A/en unknown
- 2016-09-15 CN CN202210278014.4A patent/CN114805528A/zh active Pending
- 2016-09-15 RU RU2018113442A patent/RU2770384C2/ru active
- 2016-09-15 PE PE2018000390A patent/PE20181293A1/es unknown
- 2016-09-15 EP EP16775922.4A patent/EP3350215B1/en active Active
- 2016-09-15 UA UAA201804058A patent/UA125505C2/uk unknown
- 2016-09-15 CN CN202510314078.9A patent/CN120248097A/zh active Pending
- 2016-09-15 JP JP2018513360A patent/JP7166916B2/ja active Active
- 2016-09-15 CN CN201680052527.6A patent/CN108026162B/zh active Active
- 2016-09-15 CA CA2996006A patent/CA2996006A1/en active Pending
- 2016-09-15 BR BR112018002263-2A patent/BR112018002263A2/en active Search and Examination
- 2016-09-15 WO PCT/US2016/052012 patent/WO2017049009A1/en not_active Ceased
-
2018
- 2018-03-07 CO CONC2018/0002510A patent/CO2018002510A2/es unknown
- 2018-03-13 CL CL2018000668A patent/CL2018000668A1/es unknown
- 2018-03-15 PH PH12018500577A patent/PH12018500577A1/en unknown
- 2018-04-03 US US15/944,700 patent/US10696721B2/en active Active
-
2019
- 2019-08-19 US US16/544,394 patent/US11407794B2/en active Active
- 2019-09-18 US US16/574,910 patent/US11078243B2/en active Active
- 2019-09-18 US US16/574,917 patent/US11155586B2/en active Active
-
2020
- 2020-06-29 US US16/915,387 patent/US20200325187A1/en not_active Abandoned
- 2020-07-02 CL CL2020001781A patent/CL2020001781A1/es unknown
-
2021
- 2021-06-28 AU AU2021204400A patent/AU2021204400B2/en active Active
-
2022
- 2022-06-15 JP JP2022096301A patent/JP7602514B2/ja active Active
- 2022-06-17 US US17/843,595 patent/US20230174596A1/en not_active Abandoned
-
2023
- 2023-10-30 US US18/497,741 patent/US20240247034A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013518115A5 (OSRAM) | ||
| CA2122340C (en) | Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs | |
| JP2016512255A5 (OSRAM) | ||
| JP7705160B2 (ja) | 生物活性複合体の調製 | |
| JP2018533912A5 (OSRAM) | ||
| JP2017534676A5 (OSRAM) | ||
| CN105324397A (zh) | 胰岛素-肠促胰岛素缀合物 | |
| JP2000516579A (ja) | 腸栄養性ｇｌｐ―２ペプチドのアンタゴニスト | |
| RS20050530A (sr) | Vezivna sredstva koja inhibiraju miostatin | |
| UA103154C2 (uk) | Hla-a*1101-обмежений пептид wt1 і фармацевтична композиція, яка містить його | |
| MX2011001028A (es) | Analogos truncados de polipeptidos de insulinotropicos dependientes de glucosa. | |
| TW201204392A (en) | Dipeptide linked medicinal agents | |
| MX2011008774A (es) | Conjugados citotoxicos que tienen un compuesto de unión de receptores de neuropeptidos y. | |
| WO2010147109A1 (ja) | 遺伝子組み換えゼラチン及び塩基性線維芽細胞増殖因子を含む血管新生誘導剤 | |
| CONLON et al. | Primary structure and conformational analysis of peptide methionine—tyrosine, a peptide related to neuropeptide Y and peptide YY isolated from lamprey intestine | |
| JP6598344B2 (ja) | 環状ペプチドをタンパク質構造に提示させる超汎用法 | |
| FR2677362A1 (fr) | Neuropeptides de la famille des tachykinines. | |
| RU2018113442A (ru) | Платформа на основе каркаса цистинового узла | |
| HRP20140886T1 (hr) | MUTANTI CyaA POLIPEPTIDI I POLIPEPTIDNI DERIVATI PRIKLADNI ZA DOPREMANJE IMUNOGENIÄŚNIH MOLEKULA U STANICU | |
| JP6548126B2 (ja) | Ｉｉｉ型コラーゲン産生促進剤 | |
| JP3368282B2 (ja) | 安定なポリペプチド組成物 | |
| JP6656661B2 (ja) | プレキシンの結合調節剤 | |
| CN119285744A (zh) | 逆向-反转肽 | |
| CN110678550A (zh) | 长效肾上腺髓质素衍生物 | |
| MX2011008776A (es) | Analogos de neuropeptido y con por lo menos una substitucion de aminoacido sintetico. |